Rheumatoid arthritis is generally diagnosed and treated by rheumatologists, in most countries.
Serum level of neopterin is not a marker of disease activity in treated rheumatoid arthritis patients. The results indicated that neopterin is a marker of RA but not a marker of disease activity in treated RA patients. PubMed, Clin Rheumatol, 10/03/2016.
A new window of opportunity in rheumatoid arthritis: targeting at-risk individuals. The prospective study of at–risk individuals can provide invaluable aetiological insights as well as facilitating accurate risk prediction data and in this way, high–risk individuals may be identified for preventive interventions. PubMed, Curr Opin Rheumatol, 2016 May;28(3):260-6.
Differentiation between early rheumatoid and early psoriatic arthritis by the ultrasonographic (US) study of the synovio–entheseal complex of the small joints of the hands. The US involvement of synovio–entheseal complex and US extrasynovial features may be helpful in the differential diagnosis between early rheumatoid and early psoriatic arthritis. PubMed, Clin Exp Rheumatol, 03/03/2016. (Also see Psoriasis and Psoriatic Arthritis)
Rheumatoid Arthritis: Notable Biomarkers Linking to Chronic Systemic Conditions and Cancer. Due to the complex nature of the disease, the appearance of symptoms and markers vary amongst individuals and the connections may manifest only in part. PubMed, Curr Pharm Des, 12/09/2015. (Also see Cancer)
Biomarkers for rheumatoid and psoriatic arthritis. Biomarkers are required to enable earlier diagnosis and predict prognosis in both rheumatoid arthritis and psoriatic arthritis. PubMed, Clin Immunol, 04/28/2015. (Also see Psoriasis and Psoriatic Arthritis)
Surface APRIL Is Elevated on Myeloid Cells and Is Associated with Disease Activity in Patients with Rheumatoid Arthritis. Surface APRIL is elevated in circulating myeloid cells in patients with RA where it is highly correlated with disease activity. PubMed, J Rheumatol, 03/01/2015.
Seronegative rheumatoid arthritis (RA): Pathogenetic and therapeutic aspects. Focusing on seronegative RA, this review considers these concepts and their implications for the management of patients with this challenging, though sometimes overlooked, condition. PubMed, Best Pract Res Clin Rheumatol, 2014 Aug;28(4):651-659.
Recognition of new citrulline containing peptide epitopes by autoantibodies produced in vivo and in vitro by B cells of Rheumatoid arthritis patients. Anti-citrullinated peptide/protein antibodies (ACPAs) are highly sensitive and specific markers of rheumatoid arthritis (RA). Identification of peptide epitopes that may detect different subgroups of RA patients might have diagnostic and prognostic significance. Immunology, 10/04/2013.
Enzyme-Activating Antibodies Revealed As Marker For Most Severe Form Of Rheumatoid Arthritis. This study represents the first evidence of an antibody having a direct role in generating the targets of the immune response. Johns Hopkins Medicine, 05/22/2013.
Reading Voices of Scleroderma Books: Diana Kramer.
Sharing Scleroderma Awareness Bracelets: Deb Martin, Brenda Miller, Vickie Risner.
Thanks to UNITED WAY donors of Central New Mexico and Snohomish County!
Patricia Ann Black: Marilyn Currier, Shelley Ensz, Richard Howitt, Gerald and Pat Ivanejko, Juno Beach Condo Association, Keith and Rosalyn Miller, and Elaine Wible.
Gayle Hedlin: Daniel and Joann Pepper and Nancy Smithberg.
Janet Paulmenn: Anonymous, Mary Jo Austin, Shelley Blaser, Susan Book, Dennis and Pat Clayton, Grace Cunha, Cindy Dorio, Michael and Patricia Donahue, Shelley Ensz, Nancy Falkenhagen, Jo Frowde, Alice Gigl, Margaret Hollywood, Karen Khalaf and Family, Susan Kvarantan, Bradley Lawrence, Jillyan Little, Donna Madge, Michele Maxson, Barry and Judith McCabe, John Moffett, My Tribute Foundation, Joan-Marie Permison, John Roberts, Margaret Roof, Maryellen Ryan, Mayalin and Kiralee Murphy, Nancy Settle-Murphy, and Bruce and Elizabeth Winter.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:
International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected] to request our Welcome email, or to report bad links or to update this page content.